BioXcel Therapeutics is a clinical-stage biopharmaceutical company that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Wall Street is very bullish on both of these companies and their lead candidates, reflected in their “Strong Buy” consensus ratings, but which stock offers higher returns with over 100% upside potential? CLICK HERE.
Battle Of The “Strong Buy” Biotechs
Tags:Biopharmaceutical InvestmentsBioXcel TherapeuticsBullish MarketConsensus RatingsInvestInvestingInvestorRate of ReturnStrong Buy RatingsTg TherapeuticsUpside PotentialWall Street